Ocean Power Technologies, Inc. (NYSE:OPTT ) Q2 2025 Earnings Call July 25, 2025 9:00 AM ET Company Participants Robert Powers - Senior VP, CFO & Principal Accounting Officer Philipp Stratmann - CEO, President & Director Conference Call Participants Glenn Mattson - Ladenburg Thalmann & Co. Inc., Research Division Peter Gastreich - Water Tower Research LLC Operator Good morning, and welcome to the Ocean Power Technologies Fourth Quarter and Full Fiscal Year 2025 Earnings Conference Call. A webcast of this call is also available and can be accessed by a link on the company's website at www.oceanpowertechnologies.com.

image for news Ocean Power Technologies, Inc. (OPTT) Q4 2025 Earnings Conference Call Transcript

Here is Why Growth Investors Should Buy Agnico (AEM) Now — Positive

AEM   Zacks Investment Research — July 25, 2025

Agnico (AEM) could produce exceptional returns because of its solid growth attributes.

image for news Here is Why Growth Investors Should Buy Agnico (AEM) Now

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy — Positive

AXSM   Seeking Alpha — July 25, 2025

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file AXS-14 and Sunosi's failure in MDD studies, but ADHD data for Sunosi is encouraging. I estimate $3bn in peak revenues by the mid-2030s, which supports a Buy rating despite management's more ambitious projections.

image for news Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

3 Reasons Why Growth Investors Shouldn't Overlook Wabtec (WAB) — Positive

WAB   Zacks Investment Research — July 25, 2025

Wabtec (WAB) could produce exceptional returns because of its solid growth attributes.

image for news 3 Reasons Why Growth Investors Shouldn't Overlook Wabtec (WAB)

Here is Why Growth Investors Should Buy Calix (CALX) Now — Positive

CALX   Zacks Investment Research — July 25, 2025

Calix (CALX) could produce exceptional returns because of its solid growth attributes.

image for news Here is Why Growth Investors Should Buy Calix (CALX) Now

Victoria Greene, G Squared Private Wealth CIO, joins 'The Exchange' to discuss Tesla's path forward, opportunity Texas Instruments and

image for news G Squared's Victoria Greene: Tesla is a dumpster fire as an auto company, attractive as a tech name

Wabash National Corporation (WNC) Q2 2025 Earnings Call Transcript — Neutral

WNC   Seeking Alpha — July 25, 2025

Wabash National Corporation (NYSE:WNC ) Q2 2025 Earnings Conference Call July 25, 2025 12:00 PM ET Company Participants Brent L. Yeagy - President, CEO & Director Jacob Page - Corporate Participant Michael N.

image for news Wabash National Corporation (WNC) Q2 2025 Earnings Call Transcript

MicroStrategy Rises 131% in a Year: Buy, Sell or Hold the MSTR Stock? — Neutral

MSTR   Zacks Investment Research — July 25, 2025

MSTR's prospects are fueled by bitcoin gains and rising subscription revenues, but a premium valuation makes the stock risky.

image for news MicroStrategy Rises 131% in a Year: Buy, Sell or Hold the MSTR Stock?

SB Financial Group, Inc. (SBFG) Q2 2025 Earnings Call Transcript — Neutral

SBFG   Seeking Alpha — July 25, 2025

SB Financial Group, Inc. (NASDAQ:SBFG ) Q2 2025 Earnings Conference Call July 25, 2025 11:00 AM ET Company Participants Anthony V. Cosentino - Executive VP & CFO Mark A.

image for news SB Financial Group, Inc. (SBFG) Q2 2025 Earnings Call Transcript

Tesla Vs. Alphabet's Waymo: Which Robotaxi Company Is The Better Bet? — Neutral

GOOG  GOOGL  TSLA   Seeking Alpha — July 25, 2025

The autonomous vehicle market is set to transform urban mobility and unlock trillions in value, but most players are still in heavy R&D mode. Tesla, Inc. is pursuing a bold, camera-only approach to full self-driving, betting on scale, data, and rapid software updates for a high-risk, high-reward Robotaxi future. Alphabet Inc.'s Waymo is taking a cautious, sensor-rich route, prioritizing safety and proven operations within geofenced markets, offering a more measured - but concrete - solution.

image for news Tesla Vs. Alphabet's Waymo: Which Robotaxi Company Is The Better Bet?

Smurfit Westrock to Report Q2 Earnings: Here's What to Expect — Negative

SW   Zacks Investment Research — July 25, 2025

SW's Q2 earnings are likely to have declined as merger costs and inflationary pressures weigh on margins.

image for news Smurfit Westrock to Report Q2 Earnings: Here's What to Expect

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between November 22, 2024 and October 21, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.

image for news Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)

First Citizens BancShares, Inc.(NASDAQ:FCNCA ) Q2 2025 Earnings Call July 25, 2025 9:00 AM ET Company Participants Craig Lockwood Nix - Chief Financial Officer Deanna W. Hart - Senior Vice President of Investor Relations Elliot Howard - Corporate Participant Frank Brown Holding - Chairman & CEO Marc Einerman - Managing Director Tom Eklund - Senior Vice President & Treasurer Conference Call Participants Bernard Von Gizycki - Deutsche Bank AG, Research Division Casey Haire - Unidentified Company Christopher Edward McGratty - Keefe, Bruyette, & Woods, Inc., Research Division Christopher William Marinac - Janney Montgomery Scott LLC, Research Division Manuel Antonio Navas …

image for news First Citizens BancShares, Inc.(FCNCA) Q2 2025 Earnings Conference Call Transcript

SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.

image for news FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

Should Meta Platforms Stock Be in Your Portfolio Pre-Q2 Earnings? — Positive

META   Zacks Investment Research — July 25, 2025

META is leveraging AI to boost engagement, which attracts users and drives top-line growth, despite a stretched valuation.

image for news Should Meta Platforms Stock Be in Your Portfolio Pre-Q2 Earnings?

Can Roblox's Developer Ecosystem Fuel Its Next Growth Phase? — Positive

RBLX   Zacks Investment Research — July 25, 2025

RBLX bets big on its developer community as creator payouts surge and new tools drive record earnings momentum.

image for news Can Roblox's Developer Ecosystem Fuel Its Next Growth Phase?

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the securities of Fiserv, Inc. (“Fiserv” or the “Company”) (NYSE: FI) between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”).

image for news Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fiserv, Inc. (FI)

INTC Identity Crisis: "Why Not Just Buy AMD and NVDA?" — Negative

AMD  INTC  NVDA   Schwab Network — July 25, 2025

CFRA's Angelo Zino points to two key issues with Intel (INTC) after earnings: pressured margins despite cost-cutting measures, and a "blurry" strategic direction. He believes the company needs to put critical emphasis on its foundry and software businesses to stop to bleeding.

image for news INTC Identity Crisis: "Why Not Just Buy AMD and NVDA?"

Healthpeak Properties, Inc. (DOC) Q2 2025 Earnings Call Transcript — Neutral

DOC   Seeking Alpha — July 25, 2025

Healthpeak Properties, Inc. (NYSE:DOC ) Q2 2025 Earnings Conference Call July 25, 2025 10:00 AM ET Company Participants Andrew Johns - Senior Vice President of Investor Relations Kelvin O. Moses - Chief Financial Officer Mark Theine - Corporate Participant Scott M.

image for news Healthpeak Properties, Inc. (DOC) Q2 2025 Earnings Call Transcript

IREN vs. NBIS: Which High-Growth Mid-Cap Stands Out Right Now? — Positive

IREN  NBIS   24/7 Wall Street — July 25, 2025

Momentum investors have a lot to dig through after an explosive tech-led surge from those now-distant Liberation Day lows.

image for news IREN vs. NBIS: Which High-Growth Mid-Cap Stands Out Right Now?